samedan logo
 
 
 
spacer
home > ebr > winter 2003 > cordia-europabio convention 2003
PUBLICATIONS
European Biopharmaceutical Review

CORDIA-EuropaBio Convention 2003

Europe's first true biotechnology convention got off the ground in style in Vienna during the first week of December 2003. Approximately 1,300 delegates from 37 countries attended the Convention, which featured six plenary sessions, 60 conference panel sessions (across health care, industrial and agri-food biotechnology), six workshops, 10 different therapeutic/technology partnering sessions and an international exhibition with a range of companies from across the world.

The conference programme launched directly into the key issues that the European sector faces with the Opening Plenary featuring representation from all stakeholders in the future development of the European biotechnology industry - political, scientific, patient, mainstream industry and SMEs. The EU's Lisbon Summit objective to become the leading knowledge-based economy by 2010 is clearly not realisable on present performance. Even worse, the gap between Europe and North America is widening with Mrs Mary Harney, Deputy Prime Minister of Ireland and incoming President of the EU Competitiveness Council quoting that whilst the US is currently on average "30 per cent richer than Europe", it will be "50 per cent richer by the year 2050" if things continue as they are.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Review by Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Hansa Biopharma initiate a new Contract Development and Manufacturing project in immunological diseases

Vilnius, Lithuania, and Lund, Sweden - December 20th, 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced a new service agreement to develop the next generation of IgG cleaving enzymes.
More info >>

White Papers

Spotlight on Quality in Study Startup

Oracle Health Sciences

This white paper addresses the growing interest in quality in clinical trial execution and how workflows play an essential role by building in the steps needed to comply with TMF guidelines, reducing downstream problems. This proactive strategy limits issues caused by siloes, yielding process improvements measurable by performance metrics.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement